Abstracts tagged "Anti-CCP antibodies and juvenile idiopathic arthritis (JIA)"

Abstract Number: 320 • 2012 ACR/ARHP Annual Meeting
Evaluation of Anti-Citrullinated Type II Collagen and Anti-Citrullinated Vimentin Antibodies in Patients with Juvenile Idiopathic Arthritis
Brooke Gilliam¹, Anil K. Chauhan² and Terry L. Moore³, ¹IM-Rheumatology, Saint Louis University, St. Louis, MO, ²Rheumatology, Saint Louis University, St. Louis, MO, ³Rheumatology/Immunology, Saint Louis University, St. Louis, MO
Background/Purpose: Several studies have identified anti-cyclic citrullinated peptide (CCP) antibodies as an important indicator for destructive disease in patients with juvenile idiopathic arthritis (JIA). This…
Abstract Number: 324 • 2012 ACR/ARHP Annual Meeting
Measurement and Evaluation of Isotypes of Anti-Citrullinated Fibrinogen and Anti-Citrullinated Alpha-Enolase Antibodies in Juvenile Idiopathic Arthritis Patients
Brooke Gilliam¹, Sandra Crespo-Pagnussat², Anil K. Chauhan² and Terry L. Moore³, ¹IM-Rheumatology, Saint Louis University, St. Louis, MO, ²Rheumatology, Saint Louis University, St. Louis, MO, ³Internal Medicine/Rheumatology, Saint Louis University, Saint Louis, MO
Background/Purpose: Anti-cyclic citrullinated peptide (CCP) antibodies in juvenile idiopathic arthritis (JIA) have been identified as an important indicator for destructive disease, as is the case…
Abstract Number: 325 • 2012 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Peptide Antibody Isotyping and Identification of Citrullinated Proteins in the Synovial Fluid of Juvenile Idiopathic Arthritis Patients
Brooke Gilliam¹, Sandra Crespo-Pagnussat², Anil K. Chauhan², Reema H. Syed² and Terry L. Moore³, ¹IM-Rheumatology, Saint Louis University, St. Louis, MO, ²Rheumatology, Saint Louis University, St. Louis, MO, ³Internal Medicine/Rheumatology, Saint Louis University, Saint Louis, MO
Background/Purpose: Several citrullinated proteins have been detected in the serum and synovial fluid (SF) of rheumatoid arthritis (RA) patients. However, few studies have evaluated citrullination…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].